

Emplicure has received a research grant from Vinnova

Emplicure AB (publ) has received a research grant of SEK 1.0 million from Vinnova, Sweden's Innovation Authority, within the framework of the competence center SweDeliver.

The project "Ceramic drug carrier for tamper resistant oral drug delivery" has a total budget of SEK 2.6 million, of which Vinnova contributes SEK 1.0 million. The project aims to develop a formulation and manufacturing method for mechanically hard drug-loaded ceramic carriers with intended use for opioid use disorder or moderate to severe pain.

Each prescription of opioids carries an inherent risk of addiction. The abuse and misuse of prescription opioids frequently serve as the starting point for a lifelong struggle with addiction, emphasizing the urgent need for multiple measures to prevent addiction and overdoses.

"We are very happy about this contribution for the further development of our bioceramic material and the collaboration within SweDeliver, which strengthens the knowledge exchange in the pharmaceutical delivery area in a very positive way," says Emplicure's CEO Håkan Engqvist.

The project is a collaboration with Uppsala University, the Department of Materials Science and the competence center SweDeliver. SweDeliver is a world-leading research and competence center in drug delivery that promotes interdisciplinary collaboration between academia and industry.

"This financial reinforcement to SweDeliver's consortium provides further opportunities to conduct innovative research, of great importance and benefit for patients who are currently without optimal treatment," says Christel Bergström, director of SweDeliver.

For more information, please contact:

Håkan Engqvist

CEO

Tel: +46 (0)702 569 500

Email: hakan.engqvist@emplicure.com

Erik Magnusson

CFO

Tel: +46 (0)70 856 52 45

Email: erik.magnusson@emplicure.com

Certified Adviser

Emplicure's Certified Adviser is Erik Penser Bank.



Emplicure uses patented bioceramic technology to develop innovative and effective products to help consumers and patients live better lives. Our consumer division makes tiny, long-lasting and flavorful nicotine pouches that can be an alternative to smoking. Our pharmaceutical division develops safer and tamper-resistant treatments for pain. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com